ChemoCentryx, Inc. (CCXI)
| Previous close | 51.68 |
| Open | 51.65 |
| Bid | 51.66 x 1400 |
| Ask | 51.67 x 1300 |
| Day's range | 51.60 - 51.73 |
| 52-week range | 14.95 - 51.85 |
| Volume | |
| Avg. volume | 2,407,807 |
| Market cap | 3.716B |
| Beta (5Y monthly) | 1.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.01 |
| Earnings date | 07 Nov 2022 - 11 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 52.00 |
- Zacks
Why Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Why Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?
ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three upcoming medical conferences taking place in August and September, which highlight TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and its role in ANCA-associated vasculitis, as well as the role of C5a and C5aR in severe hidradenitis suppurativa (HS) and lupus nephritis (LN). 18th European Meeting on Complem
